Citations 2
Patient and provider perspective on financial burden after an allogeneic hematopoietic cell transplantation.
Abel, Gregory A. , McNulty, Julie, Weise, Mary, Coronado, Diana Salas, Hashmi, Shahrukh K. , Tilburt, Jon C. , Albelda, Randy , Khera, Nandita , Kim, Sunny , Roy, Vivek
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e17539-e17539
Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival
Khera, Nandita , Albelda, Randy , Hahn, Theresa , Coronado, Diana Salas, Odejide, Oreofe O. , Soiffer, Robert J. , Abel, Gregory A.
Cancer Epidemiology, Biomarkers & Prevention | February 13, 2018 | Volume: 27 | Issue: 3 | Pages: 345-347
Abstract Background: Financial hardship is a growing challenge for patients with blood cancer who undergo hematopoietic cell transplantation (HCT), and it is associated with poor patient-reported outcomes. In contrast, little is known about the potential impact of patient-reported financial hardship on post-HCT survival. Methods: We sought to describe the association of financial hardship with survival after HCT in a prospectively assembled cohort of patients from three large transplant centers (n = 325). Results: There was no association between financial hardship measures assessed at 6 months post-HCT and 1- or 2-year survival after HCT. Conclusions: Patient-reported financial distress after HCT does not seem to adversely affect post-HCT survival. Impact: When assessing the effectiveness of interventions to ameliorate familial financial burden among HCT, the focus should be on patient-reported outcomes rather than survival. Cancer Epidemiol Biomarkers Prev; 27(3); 345–7. ©2018 AACR.